OSR Health CEO says two subsidiaries draw out-licensing interest as Nasdaq bid deadline nears
OSRH•CEO comments on share purchases and funding
The CEO said he has not bought more shares because he is already the largest investor and has funded multiple rounds to support R&D.
Management said it is working to preserve the Nasdaq listing organically while subsidiary business development accelerates.
Nasdaq listing deadline and subsidiary interest
OSR Holdings’ CEO said Nasdaq is expected to decide on continued listing by Aug. 18 if shares fail to close at $1.
Two subsidiaries received inbound out-licensing inquiries; one reached preliminary term-sheet talks, while the other remains early-stage.
